The goal of this clinical trial is to assess the safety and efficacy of phacoemulsification combined with one trabecular micro-bypass stent implantation (phaco-iStent) versus phacoemulsification alone in a Taiwanese population, as well as to investigate any differences in outcomes between patients with primary open angle glaucoma (POAG) and those with normal tension glaucoma (NTG). The main question it aims to answer is:

• How much do intraocular pressure (IOP) and the number of antiglaucoma medications change after iStent insertion, with subgroup analyses for POAG and NTG? Researchers will compare phacoemulsification combined with one trabecular micro-bypass stent implantation (phaco-iStent) versus phacoemulsification alone to see if IOP and the number of antiglaucoma medications decrease.

Participants will receive their regular phacoemulsification and decided whether to receive iStent by themselves.

Inclusion Criteria:

Patients evaluated by a clinician who require cataract surgery or cataract surgery combined with iStent implantation due to concomitant glaucoma and cataracts.

Exclusion Criteria:

• Eyes that have previously undergone vitrectomy or retinal surgery.
• Patients with ocular surface inflammation (e.g., corneal ulcers, orbital cellulitis, etc.).
• Patients with hypotony (intraocular pressure <5 mmHg).
• Patients with a history of globe rupture.

all IPD that underlie results in a publication

Beginning 3 months and ending 3 years after the publication of results

Eligibility for Data Access:

• Data will be shared with qualified researchers who provide a clear and scientifically valid research proposal.
• Proposals that align with the objectives of the original study or are intended for research that could contribute to the scientific understanding of the field will be considered.

Request Process:

• Interested researchers can request data by sending an email that includes a description of the intended analyses and the purpose of the research.
• No formal review process is required, but requests should demonstrate a valid scientific rationale for data access.

Mechanism for Data Sharing:

- Data will be shared via email. Once the request is received and approved, the data will be sent directly to the researcher.

Time Frame for Data Access:

- Data will be made available beginning 3 months and ending 3 years after the publication of results